Belen Garcia Prats My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment. Instituciones de las que forman parte Técnico de investigación Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Belen Garcia Prats Instituciones de las que forman parte Técnico de investigación Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR, holding more than one year experience working with oncologic mouse models in an ISO900 environment.
My name is Belén Garcia Prats, I hold a Bachelor’s Degree in Biomedical Sciences and I obtained in 2020 a MSc in Molecular Biotechnology. Hence, I am passionate about biomedical research areas such as pharmacology and toxicology, cancer biology and molecular techniques. My previous experience encompasses working in a clinical laboratory, being in charge of the realization of biochemical and immunological analysis on clinical simples. In addition, I was parto f a basic research group, where I worked with cell cultures for the study of type 2 diabetes mellitus pathogenesis. Currently, I am the in vivo laboratory technician at Drug Delivery and Targeting (DDT) group at VHIR. I have obtained the laboratory animals handling accreditation, holding more than one year experience working with oncologic mouse models in an ISO900 environment.
Proyectos Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: Ibane Abasolo Olaortua Colaboradores: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 60000 Referencia: 2021 SGR 01173 Duración: 01/01/2022 - 30/06/2025 Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo. IP: Joaquin Seras Franzoso Colaboradores: Laura García Latorre, Diego Baranda Martínez-Abasca, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Entidad financiadora: Instituto de Salud Carlos III Financiación: 99220 Referencia: PI22/01301 Duración: 01/01/2023 - 31/12/2025 Evolvable platform for designing cancer treatment strategies using nanoparticles (EVO-NANO) IP: Ibane Abasolo Olaortua Colaboradores: Joaquin Seras Franzoso, Simon Schwartz Navarro, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Entidad financiadora: EUROPEAN COMMISSION Financiación: 568847.5 Referencia: EVO-NANO_H2020FETOPEN2017 Duración: 01/10/2018 - 31/03/2022